Center-Authored Papers

Filters: Author is Small, Eric J  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2009
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
2010
Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW.  2010.  Sipuleucel-T.. Nature reviews. Drug discovery. 9(7):513-4.
2012
Tangen CM, Hussain MHA, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford DE, Vogelzang NJ et al..  2012.  Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).. The Journal of urology. 188(4):1164-9. Abstract
2013
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS et al..  2013.  Prostate cancer, version 1.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(12):1471-9. Abstract
2014
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS et al..  2014.  Prostate cancer, version 2.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5):686-718. Abstract
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PFA, Mainwaring P, Hainsworth JD et al..  2014.  Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302).. European urology. Abstract
Adult
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Aged
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Aged, 80 and over
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Androstadienes
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Androstenes
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Anilides
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Antineoplastic Agents
Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW.  2010.  Sipuleucel-T.. Nature reviews. Drug discovery. 9(7):513-4.
Antineoplastic Agents, Hormonal
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
Antineoplastic Combined Chemotherapy Protocols
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
April 2014
Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PFA, Mainwaring P, Hainsworth JD et al..  2014.  Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302).. European urology. Abstract
Bone Neoplasms
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Center-Authored Paper
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW.  2010.  Sipuleucel-T.. Nature reviews. Drug discovery. 9(7):513-4.